Physiology of Mutagenesis
University of Cambridge & MRC Cancer Unit

Dr. Andrea Degasperi

Postdoctoral Fellow

I am post doctoral researcher with a long experience working with biologists in systems biology, computational biology and genetics, with focus on cancer research.

I earned my Ph.D. at the University of Glasgow in 2011 and then worked as a post doctoral researcher for Systems Biology Ireland at the University College Dublin in Ireland, later at AstraZeneca in Cambridge, and finally joined the Nik-Zainal’s group in 2017.

My main contributions to the team are in the development of the mutational signatures framework and algorithms, along with their application for patient stratification and personalised medicine.

You can find more details about me and my work at my personal webpage here.

Published Works

  • Degasperi, A., Amarante, T. D., Czarnecki, J., Shooter, S., Zou, X., Glodzik, D., Morganella, S., Nanda, A. S., Badja, C., Koh, G., Momen, S. E., Georgakopoulos-Soares, I., Dias, J., Young, J., Memari, Y., Davies, H., & Nik-Zainal, S. (2020). A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nature cancer, 1(2), 249–263.
  • Kucab, J. E., Zou, X., Morganella, S., Joel, M., Nanda, A. S., Nagy, E., Gomez, C., Degasperi, A., Harris, R., Jackson, S. P., Arlt, V. M., Phillips, D. H., & Nik-Zainal, S. (2019). A Compendium of Mutational Signatures of Environmental Agents. Cell, 177(4), 821–836.e16.
  • Maura, F., Degasperi, A., Nadeu, F., Leongamornlert, D., Davies, H., Moore, L., Royo, R., Ziccheddu, B., Puente, X. S., Avet-Loiseau, H., Campbell, P. J., Nik-Zainal, S., Campo, E., Munshi, N., & Bolli, N. (2019). A practical guide for mutational signature analysis in hematological malignancies. Nature communications, 10(1), 2969.
  • Momen, S., Fassihi, H., Davies, H. R., Nikolaou, C., Degasperi, A., Stefanato, C. M., Dias, J., Dasgupta, D., Craythorne, E., Sarkany, R., Papa, S., & Nik-Zainal, S. (2019). Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Cold Spring Harbor molecular case studies, 5(5), a004408.
  • Chopra, N., Tovey, H., Pearson, A., Cutts, R., Toms, C., Proszek, P., Hubank, M., Dowsett, M., Dodson, A., Daley, F., Kriplani, D., Gevensleben, H., Davies, H. R., Degasperi, A., Roylance, R., Chan, S., Tutt, A., Skene, A., Evans, A., Bliss, J. M., … Turner, N. C. (2020). Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nature communications, 11(1), 2662.
  • Nones, K., Johnson, J., Newell, F., Patch, A. M., Thorne, H., Kazakoff, S. H., de Luca, X. M., Parsons, M. T., Ferguson, K., Reid, L. E., McCart Reed, A. E., Srihari, S., Lakis, V., Davidson, A. L., Mukhopadhyay, P., Holmes, O., Xu, Q., Wood, S., Leonard, C., Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab), … Simpson, P. T. (2019). Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 30(7), 1071–1079.